Please login to the form below

Not currently logged in
Email:
Password:

Shire separates out neuroscience as it considers its future

Follows last year's strategic review at the Irish biotechnology firm

Shire

Shire has decided its neuroscience business would do better as a separate division and will move it out from its rare disease interests following a five-month strategic review.

The move raises speculation that it’s a precursor to the unit’s divestment, particularly given Shire’s stated strategy of becoming ‘the leading global biotech company focused on rare diseases’.

Commenting on the change the Irish biotech said there was a strong business rationale for creating the two divisions, given their “distinct strategic priorities”.

In a statement that company said it was “continuing to evaluate all strategic alternatives, including the merits of an independent listing for each of the two divisions”, with the review’s second stage expected to report before the end of the year.

Historically dependent on just one ADHD treatment - Adderall -, neuroscience has dwindled in the face of Shire’s rising presence in orphan drugs and last year it accounted for less than a quarter of the firm’s $11bn revenue.

The company also faces outside pressures, and shortly before Christmas was mentioned in the press as a possible big pharma takeover target after the failure of a pivotal trial for its Hunter syndrome therapy.

The company’s new neuroscience division will look to build on its ADHD heritage and newer products like Intuniv, Vyvanse and Mydayis, the latter of which was recently launched in the US.

Meanwhile, Shire’s rare disease business - which accounts for 70% of revenues - has been growing apace, receiving a significant boost from the $32bn merger with Baxalta in 2016.

CEO Flemming Ornskov said: “Shire has undergone a significant transformation over the last five years creating two market-leading businesses with distinct profiles and future needs.

“Simultaneously, Shire has established a strong track record of growth and execution. Our new Rare Disease and Neuroscience Divisions will be well positioned for growth, profitability, innovation, and serving the needs of patients.”

Shire’s announcement came just days after pharma giant Pfizer exited early-stage Alzheimer’s and Parkinson’s R&D to allow it to make more effective use of its neuroscience research investments.

Article by
Dominic Tyer

9th January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics